ArticleSkin health and disease2026
Evaluating the effectiveness of integrating a clinical pharmacist into a hidradenitis suppurativa clinic within the specialty of dermatology.
Article in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ambulatory care pharmacists improve outcomes through medication management, adherence support, education and access to care. In dermatology, pharmacist integration is relatively new but may benefit patients with chronic conditions such as hidradenitis suppurativa (HS), which causes painful, inflammatory nodules and impaired quality of life. Objectives: To evaluate the impact of a dermatology pharmacist on outcomes in patients with HS. Methods: A prospective, quasiexperimental study was conducted in monthly HS clinics with a dermatology pharmacy specialist. The primary outcome was the Hidradenitis Suppurativa Quality of Life (HiSQOL) score, assessing symptoms, emotional wellbeing and functioning. Surveys were completed at baseline and at 3 and 6 months. Secondary outcomes included pharmacist interventions, categorized as medication facilitation, optimization and wound care. Results: In total, 38 patients were seen and evaluated by the clinical pharmacist. All completed baseline surveys; 30 (79%) completed the 3-month and 19 (50%) completed the 6-month follow-up. Mean HiSQOL scores improved from 19.8 at baseline to 12.7 at 3 months and 10.5 at 6 months. Paired Conclusions: Incorporating a dermatology pharmacist in HS care significantly improves patients' quality of life and provides critical support in medication access and optimization and wound care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.